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Genetic approaches to understanding the pathophysiology of complex
human traits. Genetic approaches to understanding the pathophysiology
of complex human traits, for example, hypertension, can complement
physiologic analyses and are likely to improve our ability to treat or
prevent the disease. A particularly useful approach is to perform linkage
analysis with candidate genes using intermediate phenotypes. This has
proven successful so far in identifying two genes involved in hypertension.
The first was a fusion gene mutation which linked the regulatory region of
the 11B-hydroxylase gene to the coding sequence for the protein of
aldosterone synthetase. This mutant gene is responsible for the condition
glucocorticoid-remediable aldostcronism (GRA). The intermediate phe-
notype used was increased levels of the adrenal steroids 18-oxo and
hydroxycortisol. The gene for GRA was identified using a pedigree
approach. It is likely, to identify other genes in hypertension, that the most
appropriate population to be affected would be sib pairs, that is, sibling
pairs who both have hypertension. In a recent study the angiotensinogen
gene also was linked to hypertension in individuals who had severe or early
onset hypertension. In addition, a variant of the angiotcnsinogen gene,
substitution of threonine rather than methionine at codon 235, was
specifically associated with hypertension. In a separate study, the T235
homozygote of the angiotensinogen gene was associated with the non-
modulating intermediate phenotype of essential hypertension. Since con-
verting enzyme inhibitors appear to correct the specific defect underlying
the elevated blood pressure in non-modulators, identification of the gene
potentially associated with non-modulation raises the strong possibility
that genetic screening will allow for more specific therapy.
Despite intensive physiologic investigation, the major mecha-
nisms responsible for a number of complex human diseases
remains unclear, with the consequence that therapy is not neces-
sarily directed toward the primary underlying causes. These
complex diseases span a wide spectrum including hypertension,
lipid disorders, Type II (non-insulin dependent) diabetes mellitus,
depression, schizophrenia, anxiety states, and osteoporosis. There
are at least three major obstacles which impede the identification
of the primary defects in all of these diseases: (1) the lack of
recognition that they are syndromes and not individual diseases;
(2) the variety of defects that could cause the final clinical
read-out, for example, hypertension; and (3) the complex inter-
play of several physiologic systems which regulate the final end
product of these syndromes, such as, elevated blood pressure,
increased blood glucose, depression, osteoporosis, etc. The con-
sequence of this interplay is that a wide variety of secondary
events can be activated or suppressed when this final read-out is
modified (that is, an increase in blood glucose or blood pressure)
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regardless of the cause, thereby masquerading as the primary
defect.
Complementary to physiologic analysis are genetic approaches
which are designed to identify mutations in genes which contrib-
ute to the development of the primary trait. Identification of such
mutations would clearly establish where primary genetic abnor-
malities lie, thus providing a starting point from which to deter-
mine how normal physiology is deranged, resulting in the final
clinical read-out.
Candidate gene
The general approach used to perform these types of studies is
called "linkage analysis." It is derived from the actual process that
is perfonned, that is, linking a particular trait to a specific gene [1].
How difficult this process is depends on whether a specific
candidate gene has been identified for the particular trait in
question [2, 3]. If a candidate gene has been identified, then an
assessment of the physical structure of the alleles involved in the
production of its gene product can be determined, and the altered
product identified. In some diseases with a dominant transmis-
sion, often there is a structural change within the coding region of
the gene, which greatly simplifies the identification of an altered
gene product. However, for complex traits this is unlikely to occur.
Therefore, identifying heterozygosity in these alleles usually is
accomplished by an assessment of structural differences in non-
coding regions of the gene, for example, the 3' flanking region [3].
A careful search of the candidate gene usually will yield a number
of different alleles all of which have a similar functional read-out,
but each varies in the structural characteristics of other parts of
the gene. The degree of distribution of these alleles in the general
population determines the utility of a particular gene variant or
marker as a genetic probe. Thus, if nearly everyone in the
population under investigation has a particular allele for the
candidate gene, this will not provide much information—the allele
would not be very "informative." Ideally, a number of alleles are
developed for a particular candidate gene, each of which would
have a high degree of informativeness and, therefore, would be
useful for genetic linkage studies.
General linkage analysis
When candidate genes are not known, then linkage studies can
be performed using anonymous markers [1]. In this case one uses
a series of markers which appropriately span the entire genome in
an attempt to focus in on those areas in which a particular
candidate gene may reside. This general linkage analysis is a much
1550
Williams: Genes and hypertension 1551
more arduous approach to evaluate genetic contributions, partic-
ularly to complex human traits, because of the large numbers of
genes present in the human genome.
Intermediate phenotype
After the appropriate genetic approach is established, either
general linkage or candidate gene, the next step is to determine
which population will be studied and what characteristics of that
population will be used to perform linkage to the gene(s) in
question. The usual approach is to collect large extended pedi-
grees so that one can determine not only linkage to the gene(s) in
question, but also potentially the inheritance patterns of the
gene(s) identified to be associated with a specific trait. The power
of these genetic analytical tools can be substantially increased if
the population containing the distant phenotype (trait) can be
subdivided into more homogenous subgroups, with individuals in
such subgroups having an increased prevalence of a specific gene.
Furthermore, it is anticipated that use of these "intermediate"
phenotypes will ultimately prove crucial in elucidating the physiologic
mechanism(s) by which any identified relevant genetic variant im-
parts an effect. In this approach one not only requires the subject to
have the distant phenotype, such as hypertension, but also to have a
specific intermediate phenotype [4]. Having established this, linkage
analysis with candidate genes then can be performed.
Glucocorticoid-remediable aldosteronism
An example of this approach is the identification of the gene
responsible for a subset of the hypertensive population called
glucocorticoid-remediable aldosteronism (GRA) [4, 5]. This is an
autosomal-dominant trait characterized by hypertension, sup-
pressed plasma renin activity, and control of aldosterone by
ACTH rather than its usual secretagogues angiotensin II and
potassium. In addition, patients with GRA secrete large amounts
of the abnormal adrenal steroids 18-oxo- and hydroxycortisol.
Lifton, Dluhy and their colleagues took advantage of this specific
biochemical trait—an intermediate phenotype—to identify mem-
bers of a large pedigree who had GRA. Analysis of the physiology
of GRA suggested the gene encoding aldosterone synthetase—
the last step in the synthesis of aldosterone—as a candidate gene,
which ultimately led to the demonstration of a mutation in this
gene which precisely co-segregated with GRA in this pedigree.
This mutation derives from an unequal crossing over between
aldosterone synthetase and steroid 11-f3 hydroxylase (li-OHase)
genes, resulting in a gene duplication in which the 5' regulatory
region of il-hydroxylase is fused to the coding sequences for the
protein, aldosterone synthetase. These results document the
utility of combining intermediate phenotypes with the candidate
gene strategy. It is worth noting that, as anticipated, even within
the first pedigree studied not all hypertensive subjects had GRA.
As a consequence, had these investigators used hypertension
rather than the biochemical trait (the intermediate phenotype) in
linkage analysis, evidence for linkage would have been diminished
by a factor of 100 (odds favoring linkage of 170,000:1 using
intermediate phenotype as the trait; odds favoring linkage of
1700:1 using hypertension as the trait). When genetic effects are
smaller than those seen in this extreme case, the anticipated loss
of power from heterogeneity will be even larger.
Affected sibling pairs
The gene involved in GRA was identified by using a pedigree
approach. For common traits such as obesity, hypertension, or
Type II diabetes mellitus, taking this usual approach may be of
limited value, since it is likely that new alleles contributing to an
increase in the trait, such as, blood pressure, by a variety of
mechanisms are introduced at each mating. Furthermore, in most
cases it is unlikely that a mutation—a "bad" gene—will actually be
found. A more likely scenario is the identification of minor
variants of normal genes whose regulation or function has been
modestly altered. It is this modestly-altered function in the
presence of prolonged exposure to a certain environment that
likely produces the disease. Thus, because genetic causes of these
complex traits are likely to be multiple with varying degrees of
penetrance and unknown inheritance, using affected sibling pairs
for linkage studies to candidate genes is particularly appealing,
provided two criteria are met: (1) relatively large numbers of
subjects are studied; and (2) markers on the relative genes are
highly informative as noted above [6—9]. In the affected sibling
pair approach, genetic and physiologic characteristics are ob-
tained from siblings, both of whom have the distant phenotype,
such as hypertension. Even linkage with anomalous genetic mark-
ers can be considered. However, there are two major drawbacks:
the need for even a larger study group to preserve analytical
power and the reduced power when the assumed recombination
fraction between the loci of the gene trait and marker is greater
than zero. A major limitation in the application of the affected
(for example, hypertensive) sibling pair approach is the relative
lack of power compared to maximum likelihood analysis using
classical Mendelian approaches. This limitation can be reduced
and the power of this approach substantially increased if the
heterogenous general trait population could be divided into more
genetically homogenous subsets (intermediate phenotypes), as
noted above. For example, in a study performed by Jeunemaitre et
al designed to assess the contribution of variants in the angio-
tensinogen gene to hypertension, the results of the study varied
depending on whether a general linkage approach was used or a
more homogenous subset was analyzed [10]. Linkage was not
consistently documented using hypertension alone as a trait. Such
only occurred when a subset of the hypertensive population (that
is, those with early-onset or more severe hypertension) was used.
After establishing linkage, the next step was to search for variants
in the angiotensinogen gene which are more specifically linked to
the hypertension. These investigators found 15 such variants when
they compared the structure of the gene in patients with hyper-
tension and their normal population. One of these in which
threonine (T) rather than methionine (M) was encoded at codon
235 proved to be significantly more prevalent in hypertensives
than in controls. Dividing the population into those who were
homozygotes for the T variant at codon 235 and those who were
homozygous for the M variant, these investigators showed that
T235 was associated with significantly elevated plasma angio-
tensinogen levels. These three lines of evidence, replicated in two
independent samples, implicate a variant in the angiotensinogen
gene in the pathogenesis of hypertension in this population.
Genetic research and treatment
Finally, what is the implication of genetic research to the
treatment of patients with these complex human traits? The
answer to this question can best be provided by a specific example:
since the 1970s it has been known that sodium intake reciprocally
modifies vascular and adrenal responses to angiotensin II (Ang II)
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[11, 121. This reciprocal effect results in a more appropriate and
specific response of the organism to changes in sodium intake
without simultaneously producing changes in blood pressure.
Recently, a series of studies have documented that some hyper-
tensive patients have a defect in this dietary sodium effect. In the
same patient, a decreased adrenal response to Ang II on a low salt
diet and a decreased renal blood flow (RBF) response to Ang II
on a high salt diet have been reported. These patients have been
defined as "non-modulators" because sodium intake fails to
modulate target tissue responsiveness to Ang II; those hyperten-
sive patients whose responses fall into the range of normotensives
are defined as "normal" modulators or simply "modulators"
[13—15]. Of particular importance regarding the pathogenesis of
the hypertension, non-modulators, in contrast to normal controls
and modulators, fail to increase RBF in response to a high salt
diet. Thus, sodium excretion is impaired resulting in sodium
balance being achieved at a higher total body sodium and,
consequently, a higher blood pressure due to the increased
intravascular volume, that is, sodium-sensitive hypertension
[14—16]. Based on studies performed on humans and in exper-
imental animals, a defect in the regulation of the tissue
renin-angiotensin system has been proposed to explain these
abnormalities [14—18].
Several lines of evidence suggest that the non-modulating trait
is inherited, including familial aggregation of the non-modulating
phenotype [19, 20]. Thus, non-modulation appears to be inherited
form of essential hypertension comprising perhaps 25% of the
total hypertensive population. Of therapeutic importance, the
underlying defect producing the salt sensitivity in these patients is
corrected by the administration of a converting enzyme inhibitor
[14, 21]. If non-modulators could be easily identified, specific
antihypertensive therapy could be offered. Accomplishing this
using a physiologic approach is impractical given the profound
impact dietary sodium intake has on the renal vascular and
adrenal responses in normals. Recently we tested the hypothesis
that the angiotensinogen variant associated with hypertension
described above (T235) is a determinant of the non-modulating
trait [22]. Our preliminary data strongly indicate that this is indeed
the case, thereby suggesting that a simple, easy-to-measure ge-
netic marker can identify individuals who are non-modulators.
This discovery will have an immediate impact on the specificity of
the antihypertensive therapy that can be offered to this subset of
the hypertensive population. Furthermore, identification using
this genetic marker early in the lives of individuals with strongly
positive family histories of hypertension will identify non-
modulators in the pre-hypertensive phase, potentially allowing
the implementation of specific and effective preventative pro-
grams to retard or even prevent the development of hyperten-
sion.
Thus, combining the powerful genetic tool of linkage analysis,
particularly with candidate genes and the physiologic techniques
embodied in assessing intermediate phenotypes is likely to prove
more successful than either approach alone in determining the
pathophysiology of complex common human traits such as Type II
diabetes mellitus, hypertension, atherosclerosis, obesity, etc.
These techniques not only will increase our understanding of the
pathophysiology but also will provide useful markers for the
various forms of these complex diseases which can identify
individuals for specific therapeutic and/or preventative programs.
Specificity in both of these areas should increase patient compli-
ance and thus the overall effectiveness of programs designed to
prevent the complications resulting from these diseases.
Reprint requests to Gordon H. Williams, MD,, Endocrine-Hypertension
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